Evaluation of the symptomatic treatment of residual neurological symptoms in Wilson disease.
Eur Neurol
; 64(2): 83-7, 2010.
Article
em En
| MEDLINE
| ID: mdl-20606453
ABSTRACT
The intention of this analysis was to identify patients with treated Wilson disease (WD) and residual neurological symptoms in order to determine whether or not they were undergoing any treatment in addition to the common decoppering medication. Moreover, the effects of any symptomatic medication were analyzed. Two samples of WD patients were investigated either by a mailed questionnaire survey (n = 135) or by a retrospective analysis (n = 75). A considerable proportion of patients still suffered from neurological symptoms (n = 106, 50.5%), of whom a relatively small proportion was treated symptomatically (n = 33, 31.1%). The documented effects varied substantially, with anticholinergics and botulinum toxin (against dystonia) and primidone (against tremor) apparently being the most promising compounds. Further studies are required to analyze the symptomatic treatment of WD patients with residual neurological symptoms in more detail.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Toxinas Botulínicas
/
Antagonistas Colinérgicos
/
Antidiscinéticos
/
Degeneração Hepatolenticular
/
Doenças do Sistema Nervoso
Tipo de estudo:
Diagnostic_studies
/
Evaluation_studies
/
Observational_studies
/
Risk_factors_studies
Limite:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Eur Neurol
Ano de publicação:
2010
Tipo de documento:
Article
País de afiliação:
Alemanha